Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower,
International Myeloma Foundation, and Clinical Care Options, LLC
Key Myeloma Questions for 2010:
Latest Developments in Diagnosis,
Prognosis, and Treatment
December 3, 2010
Orlando, Florida
This program is supported by educational grants from
Image: Copyright©2010 DNA Illustrations. All Rights Reserved
Latest Developments in Diagnosis, Prognosis, and Tr
T eatment
r
of Myeloma
clinicaloptions.com/oncology
Faculty
Program Chair
Brian G. M. Durie, MD
National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California
Latest Developments in Diagnosis, Prognosis, and Tr
T eatment
r
of Myeloma
clinicaloptions.com/oncology
Faculty
Philippe Moreau, MD
S. Vincent Rajkumar. MD
Professor of Clinical Hematology
Professor of Medicine
Head, Hematology Department
Chair, Myeloma Amyloidosis
University Hospital Hôtel-Dieu
Dysproteinemia Group
Nantes, France
Mayo Clinic
Rochester, Minnesota
Robert Z. Orlowski, MD, PhD
Director, Myeloma Section
Jesús F. San-Miguel, MD, PhD
Associate Professor of Lymphoma/
Head, Hematology Department
Myeloma and of Experimental Therapeutics
Professor of Medicine
Division of Cancer Medicine
Vice Director, Centro de Investigación del
The University of Texas M. D. Anderson
Cáncer
Cancer Center
Hospital Universitario de Salamanca and
Houston, Texas
Centro de Investigación del Cáncer
University of Salamanca
Antonio Palumbo, MD
Salamanca, Spain
Associate Professor
Department of Hematology
University of Turin
Torino, Italy
Latest Developments in Diagnosis, Prognosis, and Tr
T eatment
r
of Myeloma
clinicaloptions.com/oncology
Faculty Disclosures
Brian G. M. Durie, MD, has disclosed that he has received consulting
fees from Amgen, Celgene, Millennium, and Onyx.
Philippe Moreau, MD, has disclosed that he has received consulting
fees from Celgene, Janssen, and Millennium.
Robert Z. Orlowski, MD, PhD, has disclosed that he has received
consulting fees from Celgene, Cephalon, Janssen-Cilag, Millennium, and
Novartis.
Antonio Palumbo, MD, has disclosed that he has received honoraria
from Amgen, Celgene, Janssen-Cilag, and Merck and has served on the
advisory boards for Celgene and Janssen-Cilag.
S. Vincent Rajkumar, MD, has no significant financial relationships to
disclose.
Jesús F. San-Miguel, MD, PhD, disclosed that he has received
consulting fees from Celgene, Janssen, and Millennium.
Latest Developments in Diagnosis, Prognosis, and Tr
T eatment
r
of Myeloma
clinicaloptions.com/oncology
Staff Disclosures
Wilma Guerra, ELS; Edward King, MA; Andrew D. Bowser;
Gordon Kelley; Jennifer Blanchette, PhD; and Jim Mortimer have
no significant financial relationships to disclose.
The planners and managers reported the following financial
relationships to products or devices they or their spouse/life partner
have with commercial interests related to the content of this CME
activity:
The following planners and managers, Jan Hixon, RN, BSN, MA;
Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha
Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP, Patricia
Staples, MSN, NP-C, CCRN, and Gordon West, PhD, CCMP,
hereby state that they or their spouse/life partner do not have any
financial relationships or relationships to products or devices with any
commercial interests related to the content of this CME/CE activity of
any amount during the past 12 months.
Latest Developments in Diagnosis, Prognosis, and Tr
T eatment
r
of Myeloma
clinicaloptions.com/oncology
Disclosure of Unlabeled Use
This educational activity may contain discussion of
published and/or investigational uses of agents that are
not indicated by the FDA. Annenberg Center,
Postgraduate Institute for Medicine (PIM), Clinical Care
Options, and activity supporters do not recommend the
use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are
those of the faculty and do not necessarily represent the
views of the Annenberg Center, PIM, Clinical Care
Options, and activity supporters. Please refer to the official
prescribing information for each product for discussion of
approved indication, contraindications, and warnings.
Latest Developments in Diagnosis, Prognosis, and Tr
T eatment
r
of Myeloma
clinicaloptions.com/oncology
Goal
The goal of this activity is to provide education that results in
better care for patients with multiple myeloma due to improved
competence in the educational setting and performance in the
practice setting.
Target Audience
This activity is intended for hematologists, oncologists, nurses,
and other healthcare professionals who treat patients with multiple
myeloma.
Latest Developments in Diagnosis, Prognosis, and Tr
T eatment
r
of Myeloma
clinicaloptions.com/oncology
Learning Objectives
At the conclusion of this activity, participants should be able to:
Formulate optimal frontline treatment strategies for patients with
multiple myeloma, including smoldering multiple myeloma, using
cytogenetics and molecular biomarkers
Select an induction regimen for patients with multiple myeloma
undergoing autologous transplantation
Discuss effective treatment strategies for patients with newly
diagnosed or relapsed/refractory multiple myeloma
Integrate recent research findings into the construction of treatment
regimens for patients
Evaluate alternative treatment options in patients who are not
transplantation candidates
Counsel appropriately selected patients on the availability of clinical
research studies evaluating novel treatment approaches
Latest Developments in Diagnosis, Prognosis, and Tr
T eatment
r
of Myeloma
clinicaloptions.com/oncology
Physician Continuing Medical Education
Accreditation
This activity has been planned and implemented in accordance
with the Essential Areas and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the
joint sponsorship of Annenberg Center for Health Sciences at
Eisenhower (Annenberg Center) and Clinical Care Options,
LLC. The Annenberg Center is accredited by the ACCME to
provide continuing medical education for physicians.
Credit Designation
The Annenberg Center designates this educational activity for a
maximum of 3.0 AMA PRA Category 1 CreditsTM. Physicians
should only claim credit commensurate with the extent of their
participation in the activity.
Latest Developments in Diagnosis, Prognosis, and Tr
T eatment
r
of Myeloma
clinicaloptions.com/oncology
Agenda
Welcome and Introduction
Brian G. M. Durie, MD Program Chair
Diagnosis, Prognosis, and Risk Assessment in Multiple Myeloma
S. Vincent Rajkumar, MD
Evolving Treatment Approaches in Transplantation-Eligible Patients
Jesús F. San-Miguel, MD, PhD
Emerging Therapies for Transplantation-Ineligible Patients
Antonio Palumbo, MD
Consolidation and Maintenance Therapy in Myeloma
Philippe Moreau, MD
Novel Agents and Regimens
Robert Z. Orlowski, MD, PhD
Conclusion, Faculty Panel Commentary, and Question and
Answer Session
Latest Developments in Diagnosis, Prognosis, and Tr
T eatment
r
of Myeloma
clinicaloptions.com/oncology
Please Review the Following Important
CME Information in Your Handout
List of faculty and affiliations
Disclosures for all faculty and nonfaculty participants
involved in the development of this program
Instructions for earning CME credit
PDFs of tonight's presentations will be posted on the
Clinical Care Options Web site
Latest Developments in Diagnosis, Prognosis, and Tr
T eatment
r
of Myeloma
clinicaloptions.com/oncology
If you are a clinician, are you a:
1. Hematologist/oncologist
2. Hematologist
3. Oncologist
4. Bench scientist
5. Fellow/resident/intern
6. Advance practice nurse
7. Oncology nurse
Latest Developments in Diagnosis, Prognosis, and Tr
T eatment
r
of Myeloma
clinicaloptions.com/oncology
In which setting do you practice?
1. University setting
2. Research setting (nonuniversity)
3. Hospital/cancer center setting
4. Private oncology practice
Latest Developments in Diagnosis, Prognosis, and Tr
T eatment
r
of Myeloma
clinicaloptions.com/oncology
How many patients with multiple myeloma
do you manage annually?
1. 0
2. 1-5
3. 6-10
4. 11-20
5. 21-50
6. > 50